{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-007077","form_type":"8-K","ticker":"KLRS","cik":"0001754068","company_name":"Kalaris Therapeutics, Inc.","filed_at":"2025-01-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.722168+00:00","generated_at":"2026-05-28T01:14:59.252932+00:00","sec_items":["3.03","5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"AlloVir effects 1-for-23 reverse stock split effective Jan 15, 2025","bullets":["Reverse split at 1-for-23 ratio, approved by board on Jan 9 after stockholder vote.","Effective 4:05 pm ET Jan 15; trading on split-adjusted basis Jan 16 under ALVR.","No fractional shares; cash in lieu based on Jan 15 closing price.","Reverse split is part of preparations for proposed merger with Kalaris Therapeutics.","New CUSIP number 019818202; par value and authorized shares unchanged."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-007077","json":"https://secwatch.observer/filing/0001193125-25-007077.json","markdown":"https://secwatch.observer/filing/0001193125-25-007077.md","text":"https://secwatch.observer/filing/0001193125-25-007077.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1754068/000119312525007077/0001193125-25-007077-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1754068/000119312525007077/d900097d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T01:14:59.252932+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"119d9aa9df4ff49f573e80faefe7fd44a19dccf3","claim":"Kalaris Therapeutics, Inc.: Reverse stock split of common stock at 1-for-23 ratio via Certificate of Amendment to Third Amended and Restated Certificate of Incorporation (effective 2025-01-15).","evidence_excerpt":"On January 15, 2025, AlloVir, Inc. (“AlloVir”) filed an amendment (the “Certificate of Amendment”) to its Third Amended and Restated Certificate of Incorporation, as amended and/or restated from time to time, to effectuate a reverse stock split of AlloVir’s issued and outstanding shares of common stock, par value $0.0001 per share (the “Common Stock”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1754068/000119312525007077/0001193125-25-007077-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2025-01-15"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}